June 28, 2019
Chugai Pharmaceutical said on June 27 that its gene testing kit FoundationOne CDx Cancer Genomic Profile was approved for additional use as a companion diagnostic for the ROS1/TRK inhibitor Rozlytrek (entrectinib). Rozlytrek was given the world’s first green light on...read more